62 related articles for article (PubMed ID: 30345340)
1. Transformation from pityriasis rubra pilaris to erythema gyratum repens-like eruption without associated malignancy: A report of 2 cases.
Richey PM; Fairley JA; Stone MS
JAAD Case Rep; 2018 Oct; 4(9):944-946. PubMed ID: 30345340
[No Abstract] [Full Text] [Related]
2. Pityriasis rubra pilaris-like graft-vs-host disease following allogeneic stem cell transplant in two patients.
Wang JY; Tabata MM; Pugliese S; Phillips D; Kim J; Weng WK; Kwong BY
Clin Case Rep; 2019 Dec; 7(12):2491-2494. PubMed ID: 31893086
[TBL] [Abstract][Full Text] [Related]
3. Methotrexate and acitretin in pityriasis rubra pilaris: A retrospective cohort study.
Greenzaid JD; Hrin ML; Feldman SR; Strowd LC
J Am Acad Dermatol; 2024 Mar; 90(3):652-654. PubMed ID: 37992813
[No Abstract] [Full Text] [Related]
4. Corrigendum to "Successful treatment of a child's pityriasis rubra pilaris (PRP)with ustekinumab and acitretin"
Pediatr Dermatol; 2023; 40(5):971. PubMed ID: 37767651
[No Abstract] [Full Text] [Related]
5. Rapid improvement of severe pityriasis rubra pilaris upon treatment with bimekizumab.
Rak K; Goebeler M; Kerstan A
Int J Dermatol; 2024 May; ():. PubMed ID: 38716638
[No Abstract] [Full Text] [Related]
6. Psoriasis. ? Pityriasis Rubra Pilaris. Case for Diagnosis.
Davies JH
Proc R Soc Med; 1930 Feb; 23(4):415. PubMed ID: 19987354
[No Abstract] [Full Text] [Related]
7. A randomized placebo-controlled single-center pilot study of the safety and efficacy of apremilast in subjects with moderate-to-severe alopecia areata.
Mikhaylov D; Pavel A; Yao C; Kimmel G; Nia J; Hashim P; Vekaria AS; Taliercio M; Singer G; Karalekas R; Baum D; Mansouri Y; Lebwohl MG; Guttman-Yassky E
Arch Dermatol Res; 2019 Jan; 311(1):29-36. PubMed ID: 30417279
[TBL] [Abstract][Full Text] [Related]
8. Network meta-analyses of systemic treatments for psoriasis: a critical appraisal: Original Articles: Jabbar-Lopez ZK, Yiu ZZN, Ward V et al. Quantitative evaluation of biologic therapy options for psoriasis: a systematic review and network meta-analysis. J Invest Dermatol 2017; 137:1646-54. Sbidian E, Chaimani A, Garcia-Doval I et al. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. Cochrane Database Syst Rev 2017; 12:CD011535.
Ellis AG; Flohr C; Drucker AM
Br J Dermatol; 2019 Feb; 180(2):282-288. PubMed ID: 30347448
[TBL] [Abstract][Full Text] [Related]
9. Gastrointestinal bleeding with severe mucosal involvement in a patient with generalized pustular psoriasis without IL36RN mutation.
Komatsuda S; Kamata M; Chijiwa C; Namiki K; Fukaya S; Hayashi K; Fukuyasu A; Tanaka T; Ishikawa T; Ohnishi T; Abe K; Yamamoto T; Aozasa N; Sugiura K; Tada Y
J Dermatol; 2019 Jan; 46(1):73-75. PubMed ID: 30474867
[TBL] [Abstract][Full Text] [Related]
10. Paradoxical ulcerative colitis during treatment with secukinumab for psoriasis.
Uchida S; Oiso N; Komeda Y; Kudo M; Kawada A
Eur J Dermatol; 2019 Aug; 29(4):444-445. PubMed ID: 30442634
[No Abstract] [Full Text] [Related]
11. Ixekizumab Improved Patient-Reported Genital Psoriasis Symptoms and Impact of Symptoms on Sexual Activity vs Placebo in a Randomized, Double-Blind Study.
Yosipovitch G; Foley P; Ryan C; Cather JC; Meeuwis KA; Burge R; Bleakman AP; Lin CY; Malatestinic W; Gottlieb A
J Sex Med; 2018 Nov; 15(11):1645-1652. PubMed ID: 30415816
[TBL] [Abstract][Full Text] [Related]
12. Real-world US healthcare costs of psoriasis for biologic-naive patients initiating apremilast or biologics.
Feldman SR; Pelletier CL; Wilson KL; Mehta RK; Brouillette MA; Smith D; Bonafede MM
J Comp Eff Res; 2019 Jan; 8(1):45-54. PubMed ID: 30387367
[TBL] [Abstract][Full Text] [Related]
13. A review of ixekizumab in the treatment of psoriatic arthritis.
O'Rielly DD; Rahman P
Expert Rev Clin Immunol; 2018 Dec; 14(12):993-1002. PubMed ID: 30360663
[TBL] [Abstract][Full Text] [Related]
14. Ixekizumab (Interleukin 17A Antagonist): 12-week Efficacy and Safety Outcomes in Real-world Clinical Practice.
Georgakopoulos JR; Phung M; Ighani A; Yeung J
J Cutan Med Surg; 2019; 23(2):174-177. PubMed ID: 30449146
[TBL] [Abstract][Full Text] [Related]
15. Ixekizumab for treatment of moderate to severe plaque psoriasis: real world clinical experience.
Diotallevi F; Campanati A; Radi G; Molinelli E; Offidani A
G Ital Dermatol Venereol; 2020 Dec; 155(6):739-743. PubMed ID: 30428651
[TBL] [Abstract][Full Text] [Related]
16. Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial.
van der Heijde D; Cheng-Chung Wei J; Dougados M; Mease P; Deodhar A; Maksymowych WP; Van den Bosch F; Sieper J; Tomita T; Landewé R; Zhao F; Krishnan E; Adams DH; Pangallo B; Carlier H;
Lancet; 2018 Dec; 392(10163):2441-2451. PubMed ID: 30360964
[TBL] [Abstract][Full Text] [Related]
17. Apremilast as therapeutic option in a HIV positive patient with severe psoriasis.
Sacchelli L; Patrizi A; Ferrara F; Bardazzi F
Dermatol Ther; 2018 Nov; 31(6):e12719. PubMed ID: 30358044
[No Abstract] [Full Text] [Related]
18. Tildrakizumab: A Review of Phase II and III Clinical Trials.
Kolli SS; Gabros SD; Pona A; Cline A; Feldman SR
Ann Pharmacother; 2019 Apr; 53(4):413-418. PubMed ID: 30345790
[TBL] [Abstract][Full Text] [Related]
19. Pityriasis Rubra Pilaris: An Updated Review of Clinical Presentation, Etiopathogenesis, and Treatment Options.
Joshi TP; Duvic M
Am J Clin Dermatol; 2024 Mar; 25(2):243-259. PubMed ID: 38159213
[TBL] [Abstract][Full Text] [Related]
20. Biologic Therapies for the Management of Cutaneous Findings in Genodermatoses: A Review.
Joshi TP; Wang HY; Athukuri P; Bohac S; Farr MA; Hinson D; Kahla JA; Khalfe N; McBee DB; Stroh R; Walters N; Ren V
Am J Clin Dermatol; 2022 Sep; 23(5):673-688. PubMed ID: 35606649
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
